![[Des-Arg9]-Bradykinin acetate](https://file.medchemexpress.com/product_pic/hy-p0298a.gif "Click to View [Des-Arg9]-Bradykinin acetate Product Detail")
![Sar-[D-Phe8]-des-Arg9-Bradykinin](https://file.medchemexpress.com/product_pic/hy-103291.gif "Click to View Sar-[D-Phe8]-des-Arg9-Bradykinin Product Detail")
![[Tyr8] Bradykinin](https://file.medchemexpress.com/product_pic/hy-p3751.gif "Click to View [Tyr8] Bradykinin Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
65 Results for "
Bradykinin Receptor
" in MedChemExpress (MCE) Product Catalog:
Products (65)
65 Results for "Bradykinin Receptor" in MCE Product Catalog:
14
Target:
Research Areas:
14
14 Cited Publications
Synonyms: HOE 140 acetate
Target:
Research Areas:
2
Category:
Alkaloids Neurological Disease Quinoline Alkaloids Plants Papaver somniferum Linn. Disease Research Fields Inflammation/Immunology Papaveraceae
Target:
2
2 Cited Publications
Target:
Research Areas:
SSR240612 is a potent, and orally active specific non-peptide bradykinin B1 receptor antagonist, with Kis of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells expressing human B1 receptor, respectively.
2
2 Cited Publications
Synonyms: (S,R)-Noscapine hydrochloride
Target:
Research Areas:
Noscapine ((S,R)-Noscapine) hydrochloride is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine hydrochloride exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine hydrochloride disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine hydrochloride possesses anticancer, neuroprotective, anti-inflammatory activities, and can crosse the blood-brain barrier .
1
1 Cited Publications
Cat. No.: HY-P0298A
CAS No.: 23827-91-0
Target:
Research Areas:
Target:
Research Areas:
Synonyms: RMP 7
Target:
Research Areas:
Target:
Research Areas:
ELN-441958 is a potent, neutral, competitive and selective bradykinin B1 receptor antagonist with a Ki of 0.26 nM against native human bradykinin B1 receptor. ELN-441958 has high oral bioavailability, and has low CNS exposure in the mouse .
Cat. No.: HY-W704574
CAS No.: 77102-28-4
Research Areas:
Mergetpa is a reversible Arg-carboxypeptidase inhibitor with high affinity. Mergetpa reduces B1R. Mergetpa blocks the overexpression of IL-1β protein and mRNA in glucose-fed rats. Mergetpa significantly increases the expression of IL-1β protein in the renal cortex. Mergetpa is used to block the conversion of kinins and B2 receptor antagonists into metabolites lacking the C-terminal arginine. Mergetpa inhibits the time-dependent enhancement of the response of isolated rabbit aorta to bradykinin. Mergetpa preserves the chemotactic activity of full-length SDF-1α on cells. Mergetpa reverses hyperglycemia, excessive weight gain, elevated levels of oxidative stress markers and overexpression of inflammatory markers in glucose-fed rats .
Cat. No.: HY-168906
CAS No.: 1119282-90-4
Target:
Research Areas:
BI-113823 is an orally active, blood-brain barrier-permeable bradykinin B1 receptor antagonist, with a Ki value of 5.3 nM for human receptors and 13.3 nM for rat receptors. BI-113823 reduces inflammation-induced mechanical hyperalgesia, as well as the mechanical sensitivity of peripheral afferent nerves and spinal nociceptive-specific neurons. BI-113823 alleviates liver fibrosis and portal hypertension, and improves survival in chronic liver disease models. BI-113823 inhibits the activities of monocytes, neutrophils and hepatic stellate cells, as well as the PI3K/Akt signaling pathway. BI-113823 can be used in research related to inflammatory pain, liver fibrosis and portal hypertension .
Cat. No.: HY-18060
CAS No.: 639489-84-2
Synonyms: TC-5619
Target:
Research Areas:
Bradanicline (TC-5619) is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough .
Cat. No.: HY-121156A
CAS No.: 209788-45-4
Synonyms: LF 16-0687 hydrochloride; XY-2405 hydrochloride
Target:
Research Areas:
Anatibant (LF 16-0687; XY-2405) hydrochloride is a selective non-peptide bradykinin B2 receptor antagonist. Anatibant hydrochloride binds to the human, rat and guinea-pig recombinant B2 receptor with Ki values of 0.67 nM, 1.74 nM and 1.37 nM, respectively. Anatibant hydrochloride crosses the blood-brain barrier (BBB). Anatibant hydrochloride can be used in research on brain damage diseases .
Cat. No.: HY-139787A
CAS No.: 2304701-45-7
Synonyms: ISIS-721744; IONIS-PKK-LRX
Target:
Research Areas:
Donidalorsen (ISIS-721744; IONIS-PKK-LRX) sodium is an antisense oligonucleotide targeting prekallikrein (PKK). Donidalorsen sodium inhibits kallikrein activity and reduces the production of Bradykinin (HY-P0206) by specifically binding to and degrading PKK mRNA in the liver. Donidalorsen sodium can be used in the research of hereditary angioedema .
Cat. No.: HY-P4676
CAS No.: 71800-37-8
Target:
Research Areas:
Target:
Research Areas:
Cat. No.: HY-P3751
CAS No.: 32222-00-7
Target:
Research Areas:
Cat. No.: HY-103293A
Purity: 99.44%
Synonyms: Kallidin (380-389) (human, porcine, bovine) TFA
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Target:
Research Areas:
Fulimetibant is a Bradykinin receptor antagonist .
Cat. No.: HY-105067A
CAS No.: 922174-60-5
Synonyms: GV-1001 hydrochloride
Research Areas:
Infection Neurological Disease Inflammation/Immunology Cancer
Tertomotide hydrochloride (GV-1001 hydrochloride) is a 16-amino acid peptide derived from hTERT, with both cell-penetrating and immunostimulatory activities, and it can cross the blood-brain barrier. Tertomotide hydrochloride binds to STING, HO-1, eHSP70, eHSP90, bradykinin receptor 1, VEGFR-2, NF-κB, p38 MAPK and Smad2. Tertomotide hydrochloride induces type I interferon production, mitochondrial DNA stress and T-cell responses; inhibits HBV replication, angiogenesis, TGF-β signaling pathway, NF-κB activation, endothelial-mesenchymal transition (EndMT) and fibrosis; regulates microglia; and exerts neuroprotective, anti-inflammatory, antioxidant, anti-apoptotic and anti-tumor effects. Tertomotide hydrochloride can be used in research related to hepatitis B virus infection, Alzheimer's disease, non-small cell lung cancer, atherosclerosis and depression .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
